← MiniMed Group, Inc. Common Stock overview

MiniMed Group, Inc. Common Stock vs Lantheus: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MiniMed Group, Inc. Common Stock (MMED)

Q3 2026
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

July 2026
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

Latest
▲3

MiniMed Flex Launch Drives Strong Q1, Raised Outlook

  • MiniMed Flex pump launch MiniMed launched its smallest app-controlled insulin pump in the U.S. in June, with a new sensor and algorithm. The Flex drove new pump sales up over 20% and new prescribers up 24%, powering U.S. revenue growth to 13.1% from 1.5%.

    The Flex launch is the core new product driving MiniMed's accelerating growth and is the main reason the stock is moving.

  • Abbott sensor partnership expands Abbott began supplying its Instinct sensor for MiniMed's new pump in August, and the FDA approved Abbott's dual ketone-glucose monitor with an exclusive MiniMed integration for smart dosing. This broadens MiniMed's sensor options and strengthens its product ecosystem.

    The Abbott partnership is a new collaboration that enhances MiniMed's competitive position and future product pipeline.

  • Strong Q1 results and raised guidance MiniMed reported Q1 revenue of $843 million, up 15.8% organically, and raised full-year organic growth guidance to about 10.5%. The company narrowed its net loss to zero and reaffirmed its 16% adjusted EBITDA margin target, boosting investor confidence.

    The earnings beat and guidance raise are the key financial catalysts that directly lifted the stock price.

  • Profitability lags and hedge fund conviction weakens Despite strong revenue, adjusted EBITDA margin was only 9.9% and free cash flow was negative $90 million due to separation costs. Hedge fund holdings fell 18% in Q2, and short interest stands at 20.66% of float, signaling some caution.

    This is the main counterweight: profitability and cash flow are not yet keeping pace with revenue growth, and some investors are pulling back.

Lantheus Holdings Inc (LNTH)

Q3 2026
▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

  • Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.

    The buyout is the single biggest force driving LNTH's price and future value.

  • FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.

    A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.

  • FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.

    This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

July 2026
▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

  • Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.

    The buyout is the single biggest force driving LNTH's price and future value.

  • FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.

    A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.

  • FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.

    This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

Latest
▲2▼1

Curium's $8B buyout and new FDA approval reshape Lantheus

  • Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.

    The buyout is the single biggest force driving LNTH's price and future value.

  • FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.

    A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.

  • FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.

    This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.

© 2026 MarketIVWhy